Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996658 · ClinicalTrials.gov registry record · Phase 3
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 278
- Enrollment target
- 20
- Study locations
NCT00996658: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
NCT00996658 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Boehringer Ingelheim. The registered enrollment target is 278 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00996658, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 278 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Primary Outcome
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Linagliptin
Study Locations (20)
California
- 1218.61.01028 Boehringer Ingelheim Investigational Site - Escondido
- 1218.61.01014 Boehringer Ingelheim Investigational Site - Greenbrae
- 1218.61.01015 Boehringer Ingelheim Investigational Site - Los Angeles
- 1218.61.01042 Boehringer Ingelheim Investigational Site - Paramount
- 1218.61.01046 Boehringer Ingelheim Investigational Site - Poway
- 1218.61.01044 Boehringer Ingelheim Investigational Site - San Diego
North Carolina
- 1218.61.01007 Boehringer Ingelheim Investigational Site - Greensboro
- 1218.61.01004 Boehringer Ingelheim Investigational Site - Jacksonville
- 1218.61.01023 Boehringer Ingelheim Investigational Site - Wilmington
Georgia
- 1218.61.01049 Boehringer Ingelheim Investigational Site - Lawrenceville
- 1218.61.01008 Boehringer Ingelheim Investigational Site - Roswell
Illinois
- 1218.61.01016 Boehringer Ingelheim Investigational Site - Chicago
- 1218.61.01018 Boehringer Ingelheim Investigational Site - Chicago
Florida
- 1218.61.01009 Boehringer Ingelheim Investigational Site - Miami
Idaho
- 1218.61.01040 Boehringer Ingelheim Investigational Site - Meridian
Indiana
- 1218.61.01048 Boehringer Ingelheim Investigational Site - Lafayette
Maine
- 1218.61.01001 Boehringer Ingelheim Investigational Site - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00996658 record still lists
NCT00996658 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00996658 names 20 study sites across 11 states, led by California, North Carolina, Georgia.
Frequently Asked Questions
What is clinical trial NCT00996658 about?
NCT00996658 is a clinical study titled "Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone". The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in patients with type 2 diabetes mellitus with insufficient glycaemic con...
What is the current status of trial NCT00996658?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 278 participants. The study started on 2009-10.
What conditions does trial NCT00996658 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00996658?
The interventions under investigation include: Placebo (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT00996658?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00996658 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00996658's enrollment target sits among peer trials
278 131st of 348 higher than 218 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05489237 · 278 participants · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia